LABU240906C128000
- 11.06
- -1.03-8.52%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Market Whales and Their Recent Bets on ALNY Options
Alnylam Tumbles, BridgeBio Gains After Heart Drug Data
Alnylam Pharmaceuticals Analyst Ratings
EXCLUSIVE: Beyond The Magnificent Seven — Direxion's Egilinsky Reveals Top Sector Picks
Alnylam Says Typo In Presentation Misstated Heart Drug Benefit
Alnylam Pharmaceuticals Shares Are Trading Lower. The Company Announced Results From Its HELIOS-B Phase 3 Study of Vutrisiran, an Investigational RNAi Therapeutic in Development for the Treatment of ATTR Amyloidosis With Cardiomyopathy.
Alnylam Falls After Full Data for Heart Drug That Can Rival Pfizer's
Amgen Unusual Options Activity For August 29
AbbVie Options Trading: A Deep Dive Into Market Sentiment
J&J Submits FDA Application for Myasthenia Gravis Drug Nipocalimab
Piper Ups Neurocrine to Overweight, Says '568 Still in the Game
Intuit, Amgen And Sprott Uranium Miners ETF: CNBC's 'Final Trades'
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
New Medicare Drug Price Caps Could Help Seniors Save Over $1,000 a Year - AARP
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday
United Therapeutics Analyst Ratings
Exact Sciences Analyst Ratings
Gilead Sciences Trades in the Green for Seventh Straight Session
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna